<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585585</url>
  </required_header>
  <id_info>
    <org_study_id>Nelson #1</org_study_id>
    <nct_id>NCT00585585</nct_id>
  </id_info>
  <brief_title>Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features</brief_title>
  <official_title>A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a dose of the investigational drug betahistine
      dihydrochloride that is both well tolerated and potentially effective in treating the
      symptoms of atypical depression. Atypical depression is characterized by the ability of the
      person's mood to improve temporarily in response to positive events, as well as features such
      as increased appetite, increased sleep and severe fatigue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will start taking 50 mg of betahistine dihydrochloride on treatment day 1 (after
      baseline visit). Starting on day 4, the daily dose will be increased by adding a 50 mg dose.
      If tolerated, the daily dose will be titrated to 200 mg. At the end of week 3, the dose will
      be titrated to 300 mg.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of participants
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerable Dose of Betahistine Dihydrochloride in mg</measure>
    <time_frame>7 weeks</time_frame>
    <description>The highest betahistine dose that is well tolerated when patients are titrated from 50 mg to a maximum 300 mg of daily divided doses.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Recurrent Major Depressive Disorder With Atypical Features</condition>
  <arm_group>
    <arm_group_label>Arm 1: Betahistine dihydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral betahistine dihydrochloride; daily dose 50-300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betahistine dihydrochloride</intervention_name>
    <description>oral, 50-300 mg, daily</description>
    <arm_group_label>Arm 1: Betahistine dihydrochloride</arm_group_label>
    <other_name>SERC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have signed written informed consent

          2. Be male and/or female outpatients 18 65 years of age, inclusive

          3. For women: must be surgically sterile, 2 years postmenopausal, or, if they have
             childbearing potential, using a medically accepted method of birth control and agree
             to continue use of this method for at least 30 days after the last dose of study drug
             (i.e., barrier method with spermicide, steroidal contraceptive or intrauterine device
             [IUD])

          4. Meet DSM IV1 criteria for major depressive episode (unipolar), with atypical features

          5. Have a score of 20 or greater on the Hamilton Depression Rating, 28-item version
             (HAM-D-28)

          6. Have a complete medical and psychiatric history, physical examination, laboratory
             evaluation, and ECG before study entry.

          7. Have baseline laboratory values and ECG that are normal, or abnormalities that are
             clinically insignificant

        Exclusion Criteria:

          1. Have significant and/or unstable gastrointestinal, neurological, endocrine,
             cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease;
             organic brain disease; or cancer as determined by history, physical, ECG, and
             laboratory examination

          2. Have a history of peptic ulcer disease

          3. Have a history of severe asthma

          4. Have a current diagnosis of pheochromocytoma

          5. Are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not
             practicing medically acceptable birth control. (A blood pregnancy test will be
             performed at the screening visit)

          6. Meet criteria for DSM IV1 psychoactive substance abuse or dependence in the past month

          7. Have a history of a psychotic disorder

          8. Use any medications that, in the judgment of the investigator, might have psychotropic
             effects, or interact unfavorably with betahistine dihydrochloride including centrally
             acting antihistaminic agents

          9. Have a history of hypersensitivity to betahistine dihydrochloride

         10. Exhibit, or suggestion that they may display, behavior that will not be conducive to
             the study procedures

         11. Are at significant risk of suicide as indicated by a score of 3 or greater on item
             number 11 on the HAM-D 28

         12. Have received any investigational product within 28 days of Screening

         13. Have used any antidepressant within 7 days of Screening (14 days for MAOIs; 21 days
             for fluoxetine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <results_first_submitted>March 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 25, 2017</results_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Erik Nelson</investigator_full_name>
    <investigator_title>Adjunct Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Betahistine Dihydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betahistine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>enrollment began 7/1/2007</recruitment_details>
      <pre_assignment_details>7 patients signed consent &amp; 6 patients screen-failed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Betahistine Dihydrochloride</title>
          <description>All patients start taking betahistine dihydrochloride 50 mg, which will be increased by 50 mg up to a maximum of 300 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Receiving Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Betahistine Dihydrochloride</title>
          <description>All patients start taking betahistine dihydrochloride 50 mg, which will be increased by 50 mg up to a maximum of 300 mg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerable Dose of Betahistine Dihydrochloride in mg</title>
        <description>The highest betahistine dose that is well tolerated when patients are titrated from 50 mg to a maximum 300 mg of daily divided doses.</description>
        <time_frame>7 weeks</time_frame>
        <population>The patient did not complete the study and not enough data were collected to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Betahistine Dihydrochloride</title>
            <description>All patients start taking betahistine dihydrochloride 50 mg, which will be increased by 50 mg up to a maximum of 300 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerable Dose of Betahistine Dihydrochloride in mg</title>
          <description>The highest betahistine dose that is well tolerated when patients are titrated from 50 mg to a maximum 300 mg of daily divided doses.</description>
          <population>The patient did not complete the study and not enough data were collected to be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire Study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Betahistine Dihydrochloride</title>
          <description>All patients start taking betahistine dihydrochloride 50 mg, which will be increased by 50 mg up to a maximum of 300 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild to Moderate Gastrointestinal irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erik Nelson, MD</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-5115</phone>
      <email>erik.nelson@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

